Physician profile
Jonathan Glatt
NPI 1245763275
$699.31
in general payments reported to CMS, 2019-2025
12 companies · $99.83 in 2025
The $99.83 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.50 · 2023: $170 · 2024: $391 · 2025: $99.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $255.41 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $102.01 | 2023-2025 | Dupixent |
| Amgen INC. | $83.80 | 2023-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.80 | 2023-2024 | Ofev |
| Merz North America, INC. | $38.50 | 2022 | |
| Insmed, INC. | $33.44 | 2024 | Arikayce |
| Genzyme Corporation | $29.86 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $26.87 | 2023 | |
| Baxter Healthcare | $18.66 | 2023 | Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $16.45 | 2023 | |
| Mylan Specialty L.P. | $15.55 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $14.96 | 2024 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Glatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.